<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04752696</url>
  </required_header>
  <id_info>
    <org_study_id>CRDF-001</org_study_id>
    <nct_id>NCT04752696</nct_id>
  </id_info>
  <brief_title>Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma</brief_title>
  <official_title>A Phase 2 Study of Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Patients With Metastatic Pancreatic Ductal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiff Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiff Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this trial is to assess the efficacy of onvansertib in combination with&#xD;
      nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of&#xD;
      participants with histologically confirmed metastatic pancreatic ductal adenocarcinoma&#xD;
      (PDAC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2021</start_date>
  <completion_date type="Anticipated">March 11, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 13, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) in Participants Who Receive At Least 2 Treatment Cycles</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Each cycle is 2 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction from Baseline in Serum CA19-9 Response</measure>
    <time_frame>Baseline up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Safety Lead-in: Onvansertib + nal-IRI + leucovorin + 5-FU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first 3 participants will be administered onvansertib orally once a day at a dosing schedule of 12 mg/m^2 on Day 1 to Day 10 for two cycles, where each cycle is 2 weeks. Depending on the number of dose limiting toxicities (DLTs) experienced in the first 3 participants, additional participants may receive different dosing schedules, determining the dosing schedule to be used in the treatment period. Onvansertib will be administered in combination with 70 mg/m^2 nanoliposomal irinotecan (nal-IRI), 400 mg/m^2 leucovorin and 2400 mg/m^2 fluorouracil (5-FU).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Period: Onvansertib + nal-IRI + leucovorin + 5-FU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered onvansertib at the dosing schedule selected based on the results of the safety lead-in, in cycles of 2 weeks. Onvansertib will be administered in combination with 70 mg/m^2 nanoliposomal irinotecan (nal-IRI), 400 mg/m^2 leucovorin and 2400 mg/m^2 fluorouracil (5-FU).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onvansertib</intervention_name>
    <description>Oral capsule</description>
    <arm_group_label>Safety Lead-in: Onvansertib + nal-IRI + leucovorin + 5-FU</arm_group_label>
    <arm_group_label>Treatment Period: Onvansertib + nal-IRI + leucovorin + 5-FU</arm_group_label>
    <other_name>PCM-075</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nanoliposomal irinotecan</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Safety Lead-in: Onvansertib + nal-IRI + leucovorin + 5-FU</arm_group_label>
    <arm_group_label>Treatment Period: Onvansertib + nal-IRI + leucovorin + 5-FU</arm_group_label>
    <other_name>Onivyde</other_name>
    <other_name>Nal-IRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Safety Lead-in: Onvansertib + nal-IRI + leucovorin + 5-FU</arm_group_label>
    <arm_group_label>Treatment Period: Onvansertib + nal-IRI + leucovorin + 5-FU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Safety Lead-in: Onvansertib + nal-IRI + leucovorin + 5-FU</arm_group_label>
    <arm_group_label>Treatment Period: Onvansertib + nal-IRI + leucovorin + 5-FU</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic PDAC&#xD;
&#xD;
          -  Has received 1 prior gemcitabine-based chemotherapy as first line therapy for&#xD;
             metastatic disease. Progression after completion of neoadjuvant or adjuvant therapy of&#xD;
             &lt; 6 months in duration is considered 1 line of therapy for metastatic disease&#xD;
&#xD;
          -  Has measurable disease according to Response Evaluation Criteria in Solid Tumors&#xD;
             Version 1.1 (RECIST v1.1), defined as at least 1 lesion that can be accurately&#xD;
             measured in at least 1 dimension (longest diameter to be recorded) as &gt; 20 mm with&#xD;
             conventional techniques or as &gt; 10 mm with spiral computed tomography (CT) scan&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1&#xD;
&#xD;
          -  Must be willing and able to undergo a tissue biopsy at screening; participants who, in&#xD;
             the opinion of the investigator, do not have tissue that is accessible for biopsy are&#xD;
             excepted from this criterion&#xD;
&#xD;
          -  Women of childbearing potential: (defined as not post-menopausal for 12 months or no&#xD;
             previous surgical sterilization) and fertile men must agree to use adequate&#xD;
             contraception for the duration of study participation and for 4 months after the last&#xD;
             dose of nal-IRI. Male subjects must agree to refrain from sperm donation during the&#xD;
             study and for 4 months after the last dose of nal-IRI&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
             Signed informed consent form must be obtained prior to initiation of study evaluations&#xD;
             and/or activities&#xD;
&#xD;
          -  International Normalized Ratio (INR) &lt; 1.5 unless on warfarin&#xD;
&#xD;
          -  Participants with prior malignancy and who were treated with no evidence of active&#xD;
             disease more than 2 years from initial diagnosis are eligible&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Participants must have adequate organ and bone marrow function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with irinotecan, nal-IRI, or investigational PLK1 inhibitor&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including symptomatic congestive heart failure,&#xD;
             unstable angina pectoris, cardiac arrhythmia, and myocardial infarction within 3&#xD;
             months of initiation of therapy&#xD;
&#xD;
          -  History of interstitial pneumonitis or interstitial lung disease&#xD;
&#xD;
          -  Participants with microsatellite instability-high (MSI-H) tumors with no prior immune&#xD;
             checkpoint inhibitor exposure&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Participant has active and uncontrolled bacterial, viral, or fungal infection(s)&#xD;
             requiring systemic therapy&#xD;
&#xD;
          -  QT interval with Fridericia's correction (QTcF) &gt; 470 milliseconds. The QTcF should be&#xD;
             calculated as the arithmetic mean of the QTcF on triplicate electrocardiograms (ECGs).&#xD;
             In the case of potentially correctible causes of QT prolongation, (eg, medications,&#xD;
             hypokalemia), the triplicate ECG may be repeated once during Screening and that result&#xD;
             may be used to determine eligibility&#xD;
&#xD;
          -  Planned concomitant use of medications known to prolong the QT/QTc interval&#xD;
&#xD;
          -  Participant has undergone major surgical resection within 4 weeks prior to enrollment&#xD;
&#xD;
          -  Participant received radiotherapy, surgery, chemotherapy, or an investigational&#xD;
             therapy within 2 weeks prior to study entry&#xD;
&#xD;
          -  Participant has serious medical risk factors involving any of the major organ systems&#xD;
             such that the investigator considers it unsafe for the participant to receive an&#xD;
             experimental research drugs&#xD;
&#xD;
          -  Serious psychiatric or medical conditions that could interfere with treatment&#xD;
&#xD;
          -  Major bleeding in the last 4 weeks&#xD;
&#xD;
          -  More than 1 prior chemotherapy regimen administered in the metastatic setting&#xD;
&#xD;
          -  Unable or unwilling to swallow oral medication&#xD;
&#xD;
          -  Use of strong CYP3A4 or UGT1A1 inhibitors or strong CYP3A4 inducers. Participants&#xD;
             currently receiving these agents who are able to switch to alternate therapy are not&#xD;
             excluded. Inhibitors should be stopped at least one week prior to the first dose of&#xD;
             protocol therapy and inducers should be stopped at least two weeks prior to initiation&#xD;
             of protocol therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cardiff Oncology</last_name>
    <phone>Please email</phone>
    <email>info@cardiffoncology.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trial Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic Ductal Adenocarcinoma</keyword>
  <keyword>Onvansertib</keyword>
  <keyword>Nanoliposomal irinotecan</keyword>
  <keyword>Leucovorin</keyword>
  <keyword>Fluorouracil</keyword>
  <keyword>PLK1</keyword>
  <keyword>PLK Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Onvansertib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

